Suchergebnisse - "F0P408N6V4"

PubPharm (3.679)

71

Daratumumab-lenalidomide and daratumumab-pomalidomide in relapsed lenalidomide-exposed or refractory multiple myeloma

enthalten in: Anti-cancer drugs | 2024

von Alhaj Moustafa, M. | Parrondo, R. | Abdulazeez, M. | +15

72

Elotuzumab plus pomalidomide and dexamethasone in relapsed/refractory multiple myeloma : a multicenter, retrospective, real-world experience with 200 cases outside of controlled clinical trials

enthalten in: Haematologica | 2024

von Gentile, M. | Vigna, E. | Palmieri, S. | +44

73

In-class transition from bortezomib-based therapy to IRd is an effective approach in newly diagnosed multiple myeloma

enthalten in: Future oncology (London, England) | 2024

von Rifkin, R. | Costello, C. | Birhiray, R. | +11

74

Zanubrutinib-lenalidomide-rituximab (ZR2) in unfit diffuse large B-cell lymphoma : efficient and tolerant

enthalten in: Annals of hematology | 2024

von Wang, Y. | Xu, J. | Li, P. | +3

75

CD8+ NKs as a potential biomarker of complete response and survival with lenalidomide plus R-GDP in the R2-GDP-GOTEL trial in recurrent/refractory diffuse large B cell lymphoma

enthalten in: Frontiers in immunology | 2024

von Hontecillas-Prieto, L. | García-Domínguez, D. | Palazón-Carrión, N. | +27

76

Isatuximab, Carfilzomib, Lenalidomide, and Dexamethasone for the Treatment of High-Risk Newly Diagnosed Multiple Myeloma

enthalten in: Journal of clinical oncology : official journal of the American Society of Clinical Oncology | 2024

von Leypoldt, L. | Tichy, D. | Besemer, B. | +24

77

Elotuzumab, lenalidomide, bortezomib, dexamethasone, and autologous haematopoietic stem-cell transplantation for newly diagnosed multiple myeloma (GMMG-HD6) : results from a randomised, phase 3 trial

enthalten in: The Lancet. Haematology | 2024

von Mai, E. | Goldschmid, H. | Miah, K. | +74

ErratumIn: Lancet Haematol. 2024 Feb 7;:. - PMID 38340740

78

Ibrutinib plus rituximab and lenalidomide for primary intestinal diffuse large B-cell lymphoma relapsed after anti-CD19 CAR-T cell therapy : a case report

enthalten in: Annals of hematology | 2023

von Li, C. | Zhang, X. | Zhu, D. | +3

79

Polyclonal immunoglobulin recovery in patients with newly diagnosed myeloma receiving maintenance therapy after autologous haematopoietic stem cell transplantation with either carfilzomib, lenalidomide and dexamethasone or lenalidomide alone : Subanalysis of the randomized phase 3 ATLAS trial

enthalten in: British journal of haematology | 2023

von Kubicki, T. | Dytfeld, D. | Wróbel, T. | +22

80

Tafasitamab and lenalidomide in large B-cell lymphoma : real-world outcomes in a multicenter retrospective study

enthalten in: Blood | 2023

von Qualls, D. | Lambert, N. | Caimi, P. | +21

CommentIn: Blood. 2023 Dec 28;142(26):2232-2234. - PMID 38153771